TY - JOUR
T1 - Epidermal growth factor receptor-targeted therapy in colorectal cancer
AU - O'Dwyer, Peter J.
AU - Benson, Al B.
N1 - Funding Information:
Dr O'Dwyer has received research grant support from AstraZeneca, Eli Lilly, Bristol-Myers Squibb, Amgen, Bayer, and Cell Pathways. He has served as a consultant to and received honoraria from AstraZeneca, Merck, Bayer, 3DP, GlaxoSmithKline, Cell Therapeutics, Oxigene, and Novartis. Dr Benson has received research grant support from Bristol-Myers Squibb, GlaxoWellcome, Merck, Pharmacia & Upjohn, Aventis, Novartis, Searle, Genentech BioOncology, and ImClone Systems Incorporated.
Copyright:
Copyright 2018 Elsevier B.V., All rights reserved.
PY - 2002
Y1 - 2002
N2 - Advanced colorectal carcinoma is a major cause of morbidity and mortality in the United States and other developed countries. Thus, new therapeutic strategies are urgently needed. The expression of various growth factors, growth inhibitors, and their receptors contributes to the development of colorectal cancer as well as to the proliferation and survival of malignant cells. Approximately 65% to 70% of human colon carcinomas have been shown to express the epidermal growth factor receptor (EGFR). Several investigators have reported that EGFR expression correlates with more aggressive disease and a poorer prognosis. Epidermal growth factor receptor plays a crucial role in initiating signal transduction; thus, strategies directed towards interruption of this signaling pathway have been shown to impair tumor cell proliferation. These include anti-EGFR monoclonal antibodies, immunotoxin conjugates, and EGFR tyrosine kinase inhibitors. Preclinical and clinical trials using these new therapeutic modalities appear promising in the treatment of colorectal cancer and are reviewed in this article.
AB - Advanced colorectal carcinoma is a major cause of morbidity and mortality in the United States and other developed countries. Thus, new therapeutic strategies are urgently needed. The expression of various growth factors, growth inhibitors, and their receptors contributes to the development of colorectal cancer as well as to the proliferation and survival of malignant cells. Approximately 65% to 70% of human colon carcinomas have been shown to express the epidermal growth factor receptor (EGFR). Several investigators have reported that EGFR expression correlates with more aggressive disease and a poorer prognosis. Epidermal growth factor receptor plays a crucial role in initiating signal transduction; thus, strategies directed towards interruption of this signaling pathway have been shown to impair tumor cell proliferation. These include anti-EGFR monoclonal antibodies, immunotoxin conjugates, and EGFR tyrosine kinase inhibitors. Preclinical and clinical trials using these new therapeutic modalities appear promising in the treatment of colorectal cancer and are reviewed in this article.
UR - http://www.scopus.com/inward/record.url?scp=0037010079&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0037010079&partnerID=8YFLogxK
U2 - 10.1016/S0093-7754(02)70086-9
DO - 10.1016/S0093-7754(02)70086-9
M3 - Article
C2 - 12422309
AN - SCOPUS:0037010079
VL - 29
SP - 10
EP - 17
JO - Seminars in Oncology
JF - Seminars in Oncology
SN - 0093-7754
IS - 5
ER -